| 000 | 00913 a2200277 4500 | ||
|---|---|---|---|
| 005 | 20250513034639.0 | ||
| 264 | 0 | _c19950718 | |
| 008 | 199507s 0 0 eng d | ||
| 022 | _a0028-3878 | ||
| 024 | 7 |
_a10.1212/wnl.45.6.1233-b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHorstink, M W | |
| 245 | 0 | 0 |
_aCabergoline in Parkinson's disease. _h[electronic resource] |
| 260 |
_bNeurology _cJun 1995 |
||
| 300 |
_a1233-4 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 | _aCabergoline |
| 650 | 0 | 4 |
_aDopamine Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aErgolines _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 700 | 1 | _aBerger, H J | |
| 700 | 1 | _avan de Vlasakker, C J | |
| 773 | 0 |
_tNeurology _gvol. 45 _gno. 6 _gp. 1233-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/wnl.45.6.1233-b _zAvailable from publisher's website |
| 999 |
_c7631733 _d7631733 |
||